TheraRadar
← Back
Data updated: May 24, 2026

GALDERMA LABS LP

Big Pharma

GALDERMA LABS LP is a major pharmaceutical company focused on Dermatology, Immunology. Key products include MIRVASO.

1984
Since
17
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
11 Small Molecules
Novel Drugs (2019-2024):
2 Novel Approvals 1 First-in-Class 1 Breakthrough

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Dermatology 67%
4 drugs
Immunology 33%
2 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • NEMLUVIO leads revenue
  • 4 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis
View patent timeline →

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Compare with competitor →
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling